PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

	: Mr. SURANDER KUMAR						
AGE/ GENDER	: 48 YRS/MALE		PATIENT ID		: 16618	01	
COLLECTED BY	:		REG. NO./LAB NO.		: 122411050023		
REFERRED BY	:		REGISTRATION DATE		: 05/Nov/2024 01:50 PM		
BARCODE NO.	: 12505463		COLLECTION DATE		:05/Nov/202405:18PM		
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE		REPORTING DATE		: 05/Nov/2024 06:44PM		
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA						
Test Name		Value	Unit		Biological Reference interva		
		НАЕМ	ATOLOGY				
	GLYCO	SYLATED HA	AEMOGLOBI	N (HBA10	C)		
	dife				4.0 - 6.4		
WHOLE BLOOD	EMOGLOBIN (HbA1c):	8.5 ^H		%		4.0 - 6.4	
WHOLE BLOOD by HPLC (HIGH PERFOF ESTIMATED AVERA	EMOGLOBIN (HbA1c):			% mg/dL		4.0 - 6.4 60.00 -	
WHOLE BLOOD by HPLC (HIGH PERFOR ESTIMATED AVERA by HPLC (HIGH PERFOR	EMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) GE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY)	8.5 ^H 197.25 ^H					
WHOLE BLOOD by HPLC (HIGH PERFOF ESTIMATED AVERA by HPLC (HIGH PERFOF NTERPRETATION:	EMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) GE PLASMA GLUCOSE	8.5 ^H 197.25 ^H Diabetes associ	ATION (ADA):	mg/dL	(HBAIC) in 9	60.00 -	
WHOLE BLOOD by HPLC (HIGH PERFOF ESTIMATED AVERA by HPLC (HIGH PERFOF INTERPRETATION:	EMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) GE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN	8.5 ^H 197.25 ^H Diabetes associ		mg/dL	(HBAIC) in 9	60.00 -	
WHOLE BLOOD by HPLC (HIGH PERFOF ESTIMATED AVERA by HPLC (HIGH PERFOF INTERPRETATION: F Non dia	EMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) GE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN I REFERENCE GROUP	8.5 ^H 197.25 ^H Diabetes associ	ATION (ADA): LYCOSYLATED HE	mg/dL	(HBAIC) in 9	60.00 -	
WHOLE BLOOD by HPLC (HIGH PERFOR ESTIMATED AVERA by HPLC (HIGH PERFOR INTERPRETATION: F Non dia At	EMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) GE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN I REFERENCE GROUP Ibetic Adults >= 18 years	8.5 ^H 197.25 ^H Diabetes associ	ATION (ADA): LYCOSYLATED HE	mg/dL EMOGLOGIB <5.7 5.7 - 6.4 >= 6.5	(HBAIC) in 9	60.00 -	
WHOLE BLOOD by HPLC (HIGH PERFOR ESTIMATED AVERA by HPLC (HIGH PERFOR INTERPRETATION: F Non dia At	EMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) GE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN I REFERENCE GROUP Ibetic Adults >= 18 years Risk (Prediabetes)	8.5 ^H 197.25 ^H DIABETES ASSOCI	ATION (ADA): LYCOSYLATED HE	mg/dL MOGLOGIB <5.7 5.7 - 6.4		60.00 -	
WHOLE BLOOD by HPLC (HIGH PERFOR ESTIMATED AVERA by HPLC (HIGH PERFOR INTERPRETATION: F Non dia At Di	EMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) GE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN I REFERENCE GROUP Ibetic Adults >= 18 years Risk (Prediabetes) agnosing Diabetes	8.5 ^H 197.25 ^H DIABETES ASSOCI	ATION (ADA): LYCOSYLATED HE	mg/dL EMOGLOGIB <5.7 5.7 - 6.4 >= 6.5	< 7.0	60.00 -	
WHOLE BLOOD by HPLC (HIGH PERFOR ESTIMATED AVERA by HPLC (HIGH PERFOR INTERPRETATION: F Non dia At Di	EMOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) GE PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN I REFERENCE GROUP Ibetic Adults >= 18 years Risk (Prediabetes)	8.5 ^H 197.25 ^H DIABETES ASSOCI	ATION (ADA): LYCOSYLATED HE Sof Therapy: hs Suggested:	mg/dL EMOGLOGIB <5.7 5.7 - 6.4 >= 6.5		60.00 -	

a target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long me expectancy and no significant cardiovascular disease. patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropriate.

4.High HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications 5.Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7.Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.

*** End Of Report ***



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)

